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Abstract: 
 
TSLP is an important trigger and initiator for various atopic diseases mainly atopic 
dermatitis (AD). Activators of nuclear hormone receptors like bioactive vitamin A and 
D derivatives are known to induce TSLP up-regulation in the skin. In this study 
various combinations of synthetic specific agonists and antagonists of the retinoic 
acid receptors (RARs), retinoid X receptors (RXRs) and vitamin D receptor (VDR) 
were topically administered to mice. The aim of the study was to elucidate via which 
nuclear hormone receptor pathways TSLP is regulated and how this regulation is 
connected to the development and phenotype of atopic dermatitis. TSLP expression 
was monitored using QRT-PCR and serum TSLP levels using ELISA. Synthetic 
agonists of the VDR and RARγ as well as the natural agonist all-trans retinoic acid 
(ATRA) increased TSLP expression in the skin, while an RXR agonist was not active. 
Treatments with antagonists of RXRs and RARs in addition to RARα-agonists reduced 
skin TSLP expression. Strong activation was found after a combination of a VDR and 
an RXR agonist (ca. 5 times induction) and even stronger by an RARγ and an RXR 
agonist treatment (ca. 48 times induction). We conclude that besides VDR-mediated 
signaling mainly RARγ-RXR mediated pathways in the skin are important patho-
physiological triggers for increased skin TSLP expression. We conclude that topical 
synthesized retinoids stimulated by internal or external triggers or topically applied 
induce TSLP production and are thereby important triggers for atopic dermatitis 
prevalence. 
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Introduction 
 
Atopic dermatitis (AD) is a highly pruritic, chronic and common inflammatory disease 
of the skin being often associated with strong hereditary background (1, 2). AD 
develops in early infancy and childhood and can persist till adulthood (3) and mainly 
Th2 pathways play a critical role during pathogenesis (1). Thymic stromal 
lymphopoietin (TSLP) is an IL-7 like cytokine and was shown to be a master switch 
of allergic inflammation at the epithelial cell - dendritic cell interface leading to 
allergic sensitization (4). TSLP expression is highly expressed in keratinocytes and 
myeloid dendritic cells in acute and chronic AD skin (5-7). It plays a critical role 
during initiation of allergic diseases in mice and humans (6, 8, 9) and elevated TSLP 
levels were associated with a Th2 polarisation in numerous inflammatory diseases 
(10).  
 
Topical and systemic application of lipid ligands of the nuclear hormone receptors 
vitamin D receptor (VDR), retinoid X receptor (RXR) and retinoic acid receptor (RAR) 
trigger TSLP expression (11-14). Previously, it was reported that even selective 
ablation of the retinoid X receptor α (RXRα), which is predominant in skin, triggers 
AD and results in the development of a chronic dermatitis in mice with similarities to 
human AD (15). A Th2-like inflammatory reaction after increased TSLP expression 
was observed, suggesting that TSLP is involved in the AD-like skin syndrome.  
 
The aim of our study was to find out how selective agonists and antagonists for the 
nuclear hormone receptors VDR, RARs and RXRs influence skin TSLP expression as 
well as serum TSLP levels and what is the consequence of this regulation on atopic 
dermatitis phenotype and development. 
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Materials and methods 
 
Sensitization of mice 
8-12 weeks old female C57BL6 and BALBc mice were obtained from and housed 
within the animal facility of the University of Debrecen, Hungary. Animals were 
maintained in single cages on standard animal chow and water ad libitum. All 
experimental procedures were approved by the Committee of Animal Research of the 
University of Debrecen, Hungary (Approval number: 25/2006 DEMÁB). 
 
C57BL6 mice were anesthetized and subsequently shaved on dorsal skin sites using 
an electric razor. Retinoid receptor-specific agonists and antagonists were applied 
topically each other day in 25 µl acetone (vehicle/control; Merck, Darmstadt, D) per 
treatment for two weeks. According to previous studies by other groups (16, 17) 
agonists and antagonists were applied in the following concentrations: ATRA 40 
nmol; LG268 (RXR-agonist) 100 nmol; BMS753 (RARα agonist) 40 nmol; BMS189961 
(RARγ agonist) 40 nmol; BMS493 (RAR pan-antagonist) 100 nmol; UVI3003 (RXR 
pan-antagonist) 100 nmol; MC903 (VDR agonist) 1 nmol. On day 14, four hours after 
the last treatment, mice were sacrificed, sera and full thickness skin biopsies were 
collected, skin specimens were shock frozen in liquid nitrogen and all samples were 
kept at -80 °C until analyses. Skin samples were obtained from equal body sites by 
means of the same procedure for each mouse in order to control for variability 
among specimen. Samples were visibly controlled to ensure no excessive adipose 
tissue remained, though some contamination with remaining adipose tissue cannot 
be excluded. 
 
Sensitization of BALBc mice was performed by repetitive systemic application of OVA. 
Briefly, mice were sensitized at days 47, 60 and 67 with 10 μg OVA intraperitoneally 
(i.p.) adsorbed to 1.5 mg aluminium hydroxide (Al(OH)3) or with phosphate-buffered 
saline (PBS, control). For combined treatment mice were sensitized i.p. on days 1, 14 
and 21 with 10 μg OVA adsorbed to 1.5 mg Al(OH)3. This was followed by topical 
application of 100 μg OVA adsorbed to 1.5 mg Al(OH)3 in 100 μl PBS onto shaved 
back skin, divided into four applications of 25 μl every other day of one week. 
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Epicutaneous treatment was repeated for a total exposure of three weeks separated 
by two-week intervals. Three days after the last treatment mice were euthanized; 
serum samples were collected and kept at -80 °C until analyses. 
 
Study using human atopic dermatitis volunteers 
After informed consent and the approval of the local Ethics Committee of the 
University of Debrecen, Hungary, Medical and Health Science Center, peripheral 
blood was collected from 20 AD-patients (8 male, 12 female; mean age 20 years, 
range 15-32 years). A group of 20 healthy age-matched volunteers (6 males, 14 
females, mean age 21 years, range 19-24 years) served as controls in this study 
(18). All AD-patients fulfilled the diagnostic criteria established by Hanifin and Rajka 
(19).  
 
RNA preparation and reverse transcription  
Total RNA was isolated from frozen skin using Tri® reagent (Molecular Research 
Center Inc., Cincinnati, OH) following the manufacturer’s instructions. 750 ng of total 
RNA were reverse transcribed into cDNA in a 30 µl reaction using the High Capacity 
cDNA Reverse Transcription Kit (Life Technologies, Budapest, H) according to the 
manufacturer’s protocol. 
 
Analysis of mRNA expression  
mRNA expression in skin was determined by means of quantitative real time-PCR 
(qRT-PCR) and TaqMan® Low Density Arrays (TLDA) on an ABI Prism 7900. qRT-PCR 
measurements were performed in triplicate using pre-designed TaqMan® Gene 
Expression Assays and reagents; TaqMan® Low Density Array cards were used for 
duplicate determinations using TaqMan® Gene Expression Master Mix (all Applied 
Biosystems Applera Hungary, Budapest, H). Relative quantification of mRNA 
expression was achieved using the comparative CT method and values were 
normalized to cyclophilin A mRNA. Gene expression values below detection limit were 
assumed to be zero for the purpose of statistical analysis. 
 
ELISA 
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Quantikine human TSLP and mouse TSLP kits (RnD-Sytems, Budapest, H) were used 
for the quantitative determination of human and mouse TSLP in serum. All samples 
and standards were assayed in triplicate. 100 μl of Assay Diluent RD1X was added to 
each well and 50 μl standard, control or sample was added per well. The plate was 
incubated for 2 h at RT and covered securely with a foil plate sealer. Each well was 
aspirated and washed 4 times and 200 μl of conjugate was added to each well and 
incubated for 2 h at RT. The aspirating and washing step was repeated 4 times and 
200 μl of substrate solution was added to each well and incubated for 30 min being 
protected from light. The reaction was stopped by adding 50 μl of stop solution to 
each well. The results were read within 30 min at 450 nm, with a λ correction 540 or 
570 nm. The average of the duplicate readings has been calculated for each 
standard and sample.  
 
Statistics 
Data are indicated as mean and standard error mean. Statistical analysis of QRT-PCR 
and ELISA data was performed using student t-test and differences were considered 
significant at p<0.05. 
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Results 
 
Increased TSLP expression upon synthetic RARγ-agonist (BMS189961), 
combinative RARγ-agonist-RXR-agonist and ATRA treatment in mouse skin 
(Fig. 1): Topical application of the RXR-agonist (LGD268) resulted in no significant 
change of TSLP expression in mouse skin, while the application of an RXR-antagonist 
(UVI3003) decreased TSLP expression (p<0.01) (Fig. 1A). An RARα-agonist 
(BMS753) reduced, while an RARγ-agonist increased dermal TSLP expression. Topical 
application of ATRA also significantly increased TSLP expression, while an RAR-pan 
antagonist (BMS493) significantly reduced it (Fig. 1B). Combinative application of an 
RARγ-agonist and an RXR-agonist significantly increased TSLP expression up to ca. 
50 times (Fig. 1C). 
 
Increased TSLP expression upon combinative VDR-agonist-RXR-agonist 
treatment in mouse skin (Fig. 2): Topical application of a VDR-agonist (calcitriol, 
MC903) showed a tendency of increased TSLP expression (p=0.08), while the 
combination with an RXR-agonist significantly increased TSLP expression ca. 5 times. 
Respectively, an RXR-agonist alone did not display significant influence on TSLP 
expression.  
 
Non-elevated serum TSLP concentration in human atopic dermatitis and in 
a mouse atopic dermatitis model (Fig. 3): TSLP levels were comparable in the 
serum of AD-patients in comparison to healthy volunteers. In mice after 
intraperitoneal OVA treatment we also observed comparable serum TSLP levels 
compared to controls. After intraperitoneal and epicutaneous OVA sensitization the 
serum TSLP concentration also remained comparable to PBS treated mice.  
 
After topical treatments with an RXR-agonist or an RARα-agonist comparable TSLP 
levels were found in serum, while after treatment with an RXR-antagonist a tendency 
of reduced TSLP levels were observed (p=0.08). Topical treatments with RARγ-
agonist, VDR-agonist and ATRA result in increased serum TSLP levels. 
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Discussion 
 
TSLP is implicated in the pathogenesis of AD as well as the atopic march starting 
from skin inflammation towards other allergic diseases (20-23). Mainly epithelial 
cells, especially keratinocytes, express TSLP (5) and stimulation with allergens 
increases dermal TSLP expression (9). Various studies report that nuclear hormone 
mediated signaling via RARs, RXRs and VDR-mediated pathways is involved in atopic 
sensitization, atopic phenotype and potential atopic dermatitis treatment. In this 
study we found that besides VDR-RXR signaling pathways mainly RARγ-RXR-
pathways are of major importance for increased skin TSLP expression and serum 
TSLP levels (24).  
 
Atopic dermatitis is a chronic inflammatory skin disease with a strong hereditary 
background (25). Local inflammation and missense mutated epidermal structural 
proteins are responsible for epidermal barrier dysfunction resulting in increased 
percutaneous penetration of exogenous substances. Its consequences are increased 
allergic sensitization towards normally harmless allergens and further chronification 
(26, 27). Serum TSLP levels were low in serum of healthy volunteers and non altered 
in serum of AD-patients (28, 29), while just in adults with a loss-of-function 
mutations within the filaggrin gene resulted in increased TSLP serum levels (27). In 
serum of atopic children during early sensitization increased TSLP levels were found 
(30) displaying a more skin dependent and acute phase relevant influence of TSLP. 
In our study we confirmed that serum TSLP levels were non-altered in human atopic 
dermatitis patients as well as in mice with systemic or systemic plus topical 
sensitization (Figure 3). 
 
Nuclear hormone receptors, which mainly form heterodimers with RXRs, play 
important roles for in skin physiology (31, 32). Especially the retinoid receptors (RAR) 
RARα and RARγ are crucial for skin homeostasis and skin inflammation (16) and 
application of selective synthetic RARγ ligands induced epidermal hyperproliferation 
(33). In addition, ablated RXRαβ (ep-/-) keratinocytes in mice generate a chronic 
dermatitis which displays high similarity to human AD (34). In VDR -/- animals (35) 
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and treatments with the endogenous VDR-agonist 1,25-(OH)2-vitamin D3 (1,25VD3) 
induced AD-like syndromes in mice (36). Topical application of a synthetic RAR-
ligand and especially co-treatments of an RAR- and a VDR-agonist strongly increased 
skin TSLP expression and serum TSLP levels (11). Our study and others (29) could 
not or just partly confirm this effect of 1,25VD3 treatment on TSLP expression in the 
skin. This displayed that VDR- and RAR-agonists are involved in increased skin TSLP 
expression. In our studies we found; a) that a synthetic VDR-agonist displays just a 
tendency for increasing skin TSLP expression and that co-application of an RXR-
agonist, which is not modifying skin TSLP expression and serum TSLP levels, results 
in increased skin TSLP expression and increased serum TSLP levels. b) In addition 
that an RARγ-agonist induced strong TSLP expression in the skin as well as increased 
TSLP levels in serum and that co-administration with an RXR-agonist resulted in 
strong dermal expression of TSLP and increased serum TSLP levels. c) We also found 
that an RARα-agonist and pan-RAR- and RXR-antagonists can reduce skin TSLP 
expression. As a conclusion, antagonizing specific RAR and RXR pathways may result 
in potential treatment strategies for AD prevention and therapy. 
 
We conclude that skin TSLP expression is minor influenced by vitamin D-mediated 
signaling but mainly via RARγ-mediated signaling in the skin. Increased RARγ-RXR 
mediated signaling may be initiated in the skin via internal or external triggers (33, 
37). We confirm by this that retinoids / vitamin A are important triggers for atopic 
sensitization (38-40). Based on that, we postulate that reducing dermal TSLP 
expression via interfering RARγ-RXR-mediated signaling and further serum TSLP 
levels might be an important strategy for prevention and therapy of AD or other 
TSLP-linked diseases.  
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Figure 1: (A) Gene expression of TSLP in mouse skin upon topical treatment with 
RXR-agonist (LG268, RXR-AG), RXR-antagonist (UVI3003, RXR-AN) vs. control 
treatment (CTRL); (B) Gene expression of TSLP in mouse skin upon topical treatment 
with RARα-agonist (BMS753, RARα-AG), RARγ-agonist (BMS189961, RARγ-AG), all-
trans retinoic acid (ATRA), RAR-pan-antagonist (BMS493, RAR-AN) vs. control 
treatment; (C) Gene expression of TSLP in mouse skin upon topical treatment with 
RARγ-agonist, RXR-antagonist and combinative treatment of RARγ-agonist and RXR-
agonist vs. control treatment. All experiments were performed with n=6 female 
animals, * - p < 0.05.  
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Figure 2: Gene expression of TSLP in mouse skin upon topical treatment with VDR-
agonist (MC903, VDR-AG), VDR-agonist and RXR-agonist, RXR-agonist vs. control 
treatment, experiments were performed with n=6 female animals- Significant 
differences were indicated by a solid line over the bars including p-values in addition 
to non-significant differences marked by a dashed line including the p-value. 
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Figure 3: (A) TSLP concentration (pg/μl) in serum of AD patients (D) vs. healthy 
volunteers (H) by ELISA method, n=20; (B) TSLP concentration (pg/μl) in mouse 
serum by ELISA method after intraperitoneal OVA administration (OVA i.p.), 
intraperitoneal and epicutaneous OVA administration (i.p. + e.c) vs. intraperitoneal 
PBS administration (PBS i.p.), n=4; (C) TSLP concentration (pg/μl) in mouse serum 
by ELISA method after topical treatment with RXR-agonist, RXR-antagonist, RARα-
agonist, RARγ-agonist, ATRA, VDR-agonist treatment vs. control treatment, n=4. 
Significant differences were indicated by a solid line over the bars including p-values 
in addition to non-significant differences marked by a dashed line including the p-
value. 
